ArticleNature2025
A neoantigen vaccine generates antitumour immunity in renal cell carcinoma.
Abstract readClinical Trial, Phase I
In one paragraph
Article in Nature, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 142 papers.
0numbers the graph read from it
0cells of the map it votes in
142citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
142 citing papers in PubMed.
- A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial.Nature communications · 2026Trial
- Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).Journal for immunotherapy of cancer · 2026Trial
- A phase II randomized trial of individualized neoantigen peptide vaccine combined with unusual radiotherapy (iNATURE) in advanced solid tumors-GCOG0028.Frontiers in immunology · 2025Trial
- Sequential axitinib and survivin vaccination unlock curative PD-1 immunotherapy in renal carcinoma.Oncoimmunology · 2026Article
- Novel lipid nanoparticle in a mRNA cancer vaccine drives tumor control via type I IFNs and effector CD8Molecular therapy. Nucleic acids · 2026Article
- A bottleneck-first evaluation of antigen delivery platforms for therapeutic cancer vaccines.Materials today. Bio · 2026Review
- Personalized neoantigen-targeting cancer vaccines in ovarian cancer: a phase 1 trial.Nature medicine · 2026Article
- Metal-organic framework nanovaccines for systemic tumour regression.Nature biomedical engineering · 2026Article
- Cholangiocarcinoma:Unveiling the cold tumor microenvironment and strategies for immune rejuvenation.Oncogene · 2026Review
- Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design.Molecular cancer · 2026Review
- Predicting Neoantigen Immunogenicity frombioRxiv : the preprint server for biology · 2026Article
- Personalized mRNA Neoantigen Vaccines in Cancer: Linking Precision Antigen Selection, Immune Remodeling, and Checkpoint Blockade.International journal of molecular sciences · 2026Review
- Developing neoantigen cancer vaccines: where are we now?Nature communications · 2026Review
- Biomimetic Virus-Like Mesoporous Silica Nanoparticles Activate NK Cells Indirectly via Monocyte Crosstalk.Nano letters · 2026Article
- Current landscape and future directions of neoantigen vaccines: A new era of personalized cancer immunotherapy.Innovation (Cambridge (Mass.)) · 2026Review
- Synthetic long peptide and DNA personalized cancer vaccines induce robust neoantigen-specific T cell responses in pancreatic cancer.Science advances · 2026Article
- Cancer Vaccine Development: Toward Artificial Intelligence-Assisted Personalized Cell Membrane Nanovaccine.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Beyond the genetic code: orchestrating epigenetic and immune landscapes with multivalent mRNA-exosome vaccines.Precision clinical medicine · 2026Review
- Reviving cancer vaccines in renal cell carcinoma: a new chapter in immunotherapy for kidney cancer.Immuno-oncology technology · 2026Review
- Recent developments in cancer immuno-interception strategies.Trends in molecular medicine · 2026Review
82 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
50 authors.
David A BraunSection of Medical Oncology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA. david.braun@yale.edu.ORCID 0000-0003-4543-5553
Giorgia MoranzoniSection for Bioinformatics, Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.ORCID 0000-0001-8065-6277
Vipheaviny CheaTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-6592-8710
Bradley A McGregorDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-8298-0289
Eryn BlassDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Chloe R TuDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Allison P VanasseTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.
Cleo FormanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Juliet FormanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Alexander B AfeyanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Nicholas R SchindlerCenter of Molecular and Cellular Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA.
Yiwen LiuDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Shuqiang LiTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-9106-6141
Jackson SouthardTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.
Steven L ChangHarvard Medical School, Boston, MA, USA.
Michelle S HirschHarvard Medical School, Boston, MA, USA.
Nicole R LeBoeufHarvard Medical School, Boston, MA, USA.
Oriol OliveDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Ambica MehndirattaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Haley GreensladeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Keerthi ShettyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Susan KlaegerBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-0074-5163
Siranush SarkizovaBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Christina B PedersenSection for Bioinformatics, Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.
Matthew MossanenHarvard Medical School, Boston, MA, USA.
Isabel CarulliTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.
Anna TarrenTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.
Joseph Duke-CohanTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.
Alexis A HowardTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.
J Bryan IorgulescuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Bohoon ShimDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Jeremy M SimonDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-3906-1663
Sabina SignorettiHarvard Medical School, Boston, MA, USA.ORCID 0000-0002-5000-9105
Jon C AsterHarvard Medical School, Boston, MA, USA.
Liudmila ElaginaBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Steven A CarrBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-7203-4299
Ignaty LeshchinerBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Gad GetzBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-0936-0753
Stacey GabrielBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Nir HacohenBroad Institute of MIT and Harvard, Cambridge, MA, USA.ORCID 0000-0002-2349-2656
Lars R OlsenSection for Bioinformatics, Department of Health Technology, Technical University of Denmark, Kongens Lyngby, Denmark.
Giacomo OliveiraDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-7435-5603
Donna S NeubergDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-2566-3145
Kenneth J LivakTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-9105-5856
Sachet A ShuklaTranslational Immunogenomics Laboratory, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-2445-3584
Edward F FritschDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-8412-5665
Catherine J Wu *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. catherine_wu@dfci.harvard.edu.ORCID 0000-0002-3348-5054
Derin B Keskin *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Patrick A Ott *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0002-4253-943X
Toni K Choueiri *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. toni_choueiri@dfci.harvard.edu.ORCID 0000-0002-9201-3217
Funding
VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI A. Heather Eliassen · 1985 to 2026
$330.6MYale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0MTreating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4MPhysician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1MProteomicsP01CA206978 · NCI · DANA-FARBER CANCER INST · PI WU, CATHERINE JU-YING · 2016 to 2025
$17.0MTraining Program in Nervous System TumorsK12CA090354 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI PLOTKIN, SCOTT R · 2001 to 2025
$16.3MPersonal tumor neoantigens for immunity against chronic lymphocytic leukemiaR01CA155010 · NCI · DANA-FARBER CANCER INST · PI Catherine Ju-Ying Wu · 2011 to 2026
$9.6MCenter of Excellence for High Throughput Proteogenomic CharacterizationU24CA270823 · NCI · BROAD INSTITUTE, INC. · PI STEVEN A CARR, MICHAEL A GILLETTE · 2022 to 2026
$5.3MProteogenomic Predictors of Recurrence in Non-small Cell Lung CancerU01CA271402 · NCI · WASHINGTON UNIVERSITY · PI STEVEN A CARR, MICHAEL A GILLETTE · 2022 to 2026
$5.0MDissecting neoepitope-specific clonal T cell populations in advanced melanoma patients vaccinated with personal neoantigen peptides partnered with local and systemic immune checkpoint InhibitionR01CA229261 · NCI · DANA-FARBER CANCER INST · PI Patrick Alexander Ott · 2018 to 2026
$3.8MSystematic identification of minor histocompatibility antigens to address GVHDR01HL157174 · NHLBI · DANA-FARBER CANCER INST · PI HO, VINCENT TRIEN-VINH, KESKIN, DERIN B · 2022 to 2025
$3.0MTumor and immune determinants of effective anti-tumor immunity in renal cell carcinomaR37CA279822 · NCI · YALE UNIVERSITY · PI David Braun · 2023 to 2026
$2.6MNCI NIH HHS K12 CA090354NCI NIH HHS P01 CA206978NCI NIH HHS P30 CA006516NCI NIH HHS P30 CA016359NCI NIH HHS P50 CA101942NCI NIH HHS R01 CA155010NCI NIH HHS R01 CA229261NCI NIH HHS R37 CA279822NCI NIH HHS R50 CA251956NCI NIH HHS T32 CA009172NCI NIH HHS T32 CA207021NCI NIH HHS U01 CA271402NCI NIH HHS U24 CA270823NHLBI NIH HHS R01 HL157174
Abstract
Personalized cancer vaccines (PCVs) can generate circulating immune responses against predicted neoantigens
Indexed as
Antigens, NeoplasmCancer VaccinesCarcinoma, Renal CellKidney NeoplasmsAdultAgedClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsFemaleHumansIpilimumabMaleMiddle AgedMutationNuclear ProteinsPrecision MedicineAntigens, NeoplasmBAP1 protein, humanCancer VaccinesClass I Phosphatidylinositol 3-KinasesDNA-Binding ProteinsIpilimumabNuclear ProteinsPBRM1 protein, humanPIK3CA protein, humanTranscription FactorsTumor Suppressor ProteinsUbiquitin ThiolesteraseVHL protein, humanVon Hippel-Lindau Tumor Suppressor Protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.